FDA To Review Baxter's Promotional Practices After Most Recent Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
A physician brochure for alpha 1-proteinase inhibitor Aralast NP prompts FDA to ask the firm to overhaul its approach to promotion and explain why "you expect these new policies and procedures to succeed."